NYSE: ALB · Specialty Chemicals

Albemarle (ALB) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Albemarle (ALB) at $110.84 a share. The stock last closed at $88.16, which puts the model's fair value 25.7% above the price. On the model's bands that reads as Undervalued.

Revalued . Price is the close of 16 Nov 2026. Albemarle Corporation.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$110.84midpoint of 2,000 simulations
Last close$88.16NYSE: ALB
Gap to fair value+25.7%fair value against price
Model verdictUndervaluedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $118.39 to $110.84 (-6.4%). Analysts cut their next-twelve-month EBITDA estimates: most of the move.

What the model makes of itThe price of $88.16 is 25.7% below it: Undervalued, on a medium evidence grade.

What's nextNext report on 10 Feb 2027. Options prices imply a move of about 15% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give ALB?

The calibrated range for ALB over 63 trading days is $74.50 to $105.21. It sits around the last close, and its width comes from the volatility that ALB's own options imply (51% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $68.18 to $175.50. In 61% of the simulations the fair value came out above the price the model ran on.

$39.70$331.02
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $110.84. Dashed line: the last close, $88.16.

Faircurve Insights · 14 Nov 2026

Albemarle Corporation is a global innovator that produces and distributes a diverse portfolio of engineered specialty chemicals. Its business is divided into three main segments: Lithium, Bromine and Catalysts.

Faircurve's model puts the fair value at $110.84 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $118.39, so the fair value moved -6.4%. In the model's own words, analysts cut their next-twelve-month EBITDA estimates: most of the move. The calibrated range over 63 trading days is $74.50 to $105.21. Ranges built this way held the price 60% of the time at this horizon, across 8,038 past valuations. The evidence grade is Medium, based on input completeness, peer count and agreement, and the spread of outcomes. It does not say whether the fair value is right.

Albemarle's overall quality score is 49 out of 100 against comparable companies. Earnings quality stands out at 100, with FCF / net income of 2.12x against a peer median of 0.82x. Stability scores 5, with 5y EBITDA margin downside volatility of 12.1 pts against a peer median of 2.3 pts. The model compares it with Solstice Advanced Materials, RPM International, Westlake, Element Solutions, Eastman Chemical, NewMarket and International Flavors & Fragrances.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does ALB report earnings, and how has the stock reacted?

Albemarle's next earnings report is scheduled for 10 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 7.0% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. ALB's 30 day implied volatility works out to about 14.7% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ALB's last 8 reports, ignoring direction, was 4.2%.

0%5%10%15%9.8%4.7%12 Feb '259.5%0.2%30 Apr '259.7%5.2%30 Jul '259.7%3.2%5 Nov '259.6%5.7%11 Feb '2611.2%1.8%6 May '269.6%3.8%5 Aug '269.3%9.1%4 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in ALB

10%15%20%25%4 Nov '26 report5 Aug '26 report6 May '26 report11 Feb '26 report15% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 18% on 14 Nov 2025, reached 21% on 6 Feb 2026 and reads 15% on 16 Nov 2026. The marks are report dates.

How does ALB score on business quality?

Albemarle's overall quality score is 49 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.156.1%ROIC8.3%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).1002.12xFCF / net income0.82x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.54-4.4%Revenue growth, trailing2.0%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.540.0%Net buybacks / market value0.2%
Balance sheetNet debt to EBITDA and interest coverage.790.03xNet debt / EBITDA2.64x
StabilityDownside volatility of the EBITDA margin over the last five years.512.1 ptsEBITDA margin downside volatility, 5y2.3 pts

How does ALB compare with similar companies?

The companies in specialty chemicals closest to Albemarle in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
SOLS Solstice Advanced Materials Inc.$64.92$66.04+1.7%Fairly valued
RPM RPM International Inc.$103.79$107.48+3.6%Fairly valued
WLK Westlake Corporation$61.63$55.30-10.3%Fairly valued
ESI Element Solutions Inc$31.75$30.70-3.3%Fairly valued
EMN Eastman Chemical Company$63.49$65.16+2.6%Fairly valued
NEU NewMarket Corporation$696.68$684.14-1.8%Fairly valued
IFF International Flavors & Fragrances Inc.$79.99$66.03-17.5%Overvalued
LYB LyondellBasell Industries N.V.$61.67$64.87+5.2%Low evidence grade

What the comparable companies' multiples alone would give for ALB, the peer-implied price, is $190.22 a share on this run. The fair value weighs that against the company's own multiple.

All specialty chemical stocks ranked by gap to fair value

Albemarle at a glance

Albemarle Corporation stands as a global innovator, producing and distributing a diverse portfolio of engineered specialty chemicals. Its business operations are divided into three principal segments: Lithium, Bromine, and Catalysts.

Market value
$11.0B
Sector
Basic Materials
Industry
Specialty Chemicals
Revenue expected, next twelve months
$5.8B
Consensus revenue growth, next fiscal year
+18.5%
Analysts with estimates
9
Beta to the US market
1.08
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. ALB was among them.

How the fair value is worked out: the model prices Albemarle on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for ALB was $118.39. As of 14 Nov 2026 it is $110.84, a change of -6.4%. Analysts cut their next-twelve-month EBITDA estimates: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Albemarle's valuation

Is Albemarle stock undervalued or overvalued?

On Faircurve's model, ALB reads as Undervalued as of 14 Nov 2026. The model's fair value is $110.84 a share against a last close of $88.16, a gap of +25.7%.

What is ALB's fair value?

$110.84 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $68.18 to $175.50.

What price range does the model give ALB?

$74.50 to $105.21 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Albemarle report earnings next?

The next report is scheduled for 10 Feb 2027. Companies can move their dates.

How much has ALB moved on past earnings reports?

Across its last 8 reports the median two session move was 4.2%, ignoring direction. The largest was +9.1% around the report of 4 Nov 2026.

How confident is the model in this valuation?

The model's evidence grade for ALB is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on ALB

The model holds no idea open on ALB today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ALB with their outcomes. A free account is enough.

Keep reading